fowlpox-NY-ESO-1 vaccine

Known as: rF-NY-ESO-1 
A cancer vaccine consisting of a recombinant fowlpox virus vector encoding an immunogenic peptide derived from the cancer-testis antigen NY-ESO-1, an… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2000-2014
02420002014

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
During cancer progression, malignant cells may evade immunosurveillance. However, evidence for immunological escape in humans is… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Recombinant poxviruses (vaccinia and fowlpox) expressing tumor-associated antigens are currently being evaluated in clinical… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
NY-ESO-1 is a prototypic cancer/testis antigen. In a recent phase I clinical trial, we vaccinated 13 patients bearing NY-ESO-1… (More)
Is this relevant?
2008
2008
NY-ESO-1, one of the most immunogenic cancer/testis antigens, provides attractive targets for cancer immunotherapy. NY-ESO-1 has… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 3
Is this relevant?
Highly Cited
2006
Highly Cited
2006
NY-ESO-1 is a cancer/testis antigen expressed in a range of human malignancies, and a number of vaccine strategies targeting NY… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2005
2005
Immunotherapy is being proposed to treat patients with hepatocellular carcinoma (HCC). However, more detailed knowledge on tumor… (More)
  • figure 1
  • table I
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2004
2004
NY-ESO-1 is a cancer/testis antigen expressed in normal adult tissues solely in the testicular germ cells of normal adults and in… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 4
Is this relevant?
2004
2004
PURPOSE For the development of peptide-based, cancer-specific immunotherapy, the identification of CTL epitopes from additional… (More)
  • figure 1
  • table 1
  • figure 3
  • figure 2
  • figure 5
Is this relevant?
2002
2002
NY-ESO-1 is one of the most immunogenic cancer antigens known to date, inducing humoral and cellular immune responses in a high… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
NY-ESO-1, a member of the cancer-testis family of antigens, is expressed in a subset of a broad range of different human tumor… (More)
Is this relevant?